Abstract: OBJECTIVE To systematically elevate the clinical efficacy and secondary prevention of Dengzhan Shengmai capsules among the patients with ischemic stroke(IS). METHODS The Cochrane Library, Pubmed, EMbase, CNKI, CBM, VIP, Wanfang Data were used to search for randomized controlled trials(RCTs) regarding the association between Dengzhan Shengmai capsules and ischemic stroke up to February 2016. Hand searching techniques were also used into randomized controlled trial in relevant journals and searching through the Google scholar. According to the inclusion and exclusion criteria, two reviewers screened literature, extracted data and assessed the methodological quality of RCTs independently. The meta-analysis was conducted with RevMan 5.3 software. RESULTS A total of 18 trials involving 4 416 patients were included. The results of the meta-analysis represented that:compared with the control group, the treatment group were associated with decreased the rate of strokeRR=0.53, 95%CI(0.39, 0.71), P<0.000 1 and the case-fatality rateRR=0.28, 95%CI(0.11, 0.68), P<0.005, the treatment group had better outcomes in clinical efficacyRR=1.22, 95%CI(1.15, 1.29), P<0.000 01 and activity of daily livingMD=9.19, 95%CI(3.41, 14.98), P=0.002. There was no significant difference in the improvement of disabilityMD=-0.04, 95%CI(-0.16, 0.07), P=0.47,RR=1.11, 95%CI(0.89, 1.40), P=0.35 and the rate of adverse reactionsRR=0.68, 95%CI(0.34, 1.37), P=0.29 between the treatment group and the control group. CONCLUSION Compared with conventional treatment, Dengzhan Shengmai capsules combine with conventional treatment can reduce the recurrent rate of stroke and case-fatality rate, the Dengzhan Shengmai capsules group has better outcomes in clinical efficacy and activity of daily living. Therec is no significant difference in the improvement of disability between the two groups. Dengzhan Shengmai capsules combine with conventional treatment do not increase the risk of adverse reaction.